What is Quris Technologies?
Founded in 2020, Quris Technologies operates at the vanguard of the health-tech sector. The company has developed a specialized Bio-AI platform designed to predict the safety and efficacy of drug candidates in human subjects with unprecedented accuracy. By simulating biological responses, Quris addresses one of the most costly and failure-prone aspects of the pharmaceutical industry: the transition from laboratory research to human clinical trials. Headquartered in Tel-Aviv, the company serves as a critical bridge between computational data science and life sciences, providing pharmaceutical partners with the insights necessary to streamline development pipelines and reduce the incidence of late-stage trial failures.
How much funding has Quris Technologies raised?
Quris Technologies has raised a total of $9M across 1 funding round:
Angel/Seed
$9M
Angel/Seed (2022): $9M with participation from iAngels, Richter Group, Glenrock Capital, Softbank Vision Fund, and Welltech Ventures
Key Investors in Quris Technologies
iAngels
A prominent venture capital firm and investment platform based in Israel, specializing in providing accredited investors with curated access to high-growth tech startups and scaleups.
Softbank Vision Fund
A global investment powerhouse focused on the transformative potential of AI, supporting founders who are building market-leading infrastructure and technology applications.
Welltech Ventures
A specialized venture capital fund dedicated to the wellness and health-tech ecosystem, leveraging a transdisciplinary approach to support innovations in personalized medicine.
What's next for Quris Technologies?
With the infusion of this latest capital, Quris Technologies is poised to scale its operational capacity and expand its research initiatives. The strategic roadmap likely involves deepening the integration of its AI models with existing pharmaceutical workflows and potentially broadening the scope of its predictive capabilities to include a wider array of therapeutic areas. As the company transitions from its foundational development phase into a period of rapid scaling, the focus will remain on validating its platform's efficacy through real-world clinical outcomes. Investors are closely monitoring the firm's ability to maintain its competitive edge in the crowded AI-driven drug discovery market, where speed and accuracy are the primary drivers of long-term value creation.
See full Quris Technologies company page
